Business
Lupuzor Update
Lupuzor Update.
About this update from Immupharma Plc
[{"type":"text","content":"\n\n\n 19 June 2023\n \nImmuPharma PLC\n(\"ImmuPharma\" or the \"Company\")\n \n \nPhase 2/3 adaptive clinical trial of P140 (Lupuzor™) in Lupus to commence following FDA meeting\n \nImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that the Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in patients with systemic lupus erythematosus (\"SLE/Lupus\") is to commence in H2 2023.\n \nKey highlights:\n \n· Following the receipt of comprehensive guidance from the Food and Drug Administration (\"FDA\") in 3 separate Type-C meetings, a Phase 2/3 adaptive clinical trial of P140 (Lupuzor™) in patients with Lupus will commence in H2 2023.\n \n· Avion Pharmaceuticals (\"Avion\") have confirmed that under the previously announced terms of the existing Licence Agreement, they will continue to support the new clinical trial design and Avion and ImmuPharma have agreed to proceed and will now begin preparatory steps for the Phase 2/3 adaptive clinical trial.\n \n· The trial design and protocol is substantially different from previous clinical trials that ImmuPharma has completed and includes maintaining subcutaneous dosing but at much higher concentrations and significant changes to ...